Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

SMARCA4-loss increases RNA Polymerase II pausing and elevates R-loops to inhibit BRCA1-mediated repair in ovarian cancer

ABSTRACT: Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare and aggressive cancer mainly affecting young women. It is driven by inactivating mutations in SMARCA4 (BRG1), a key SWI/SNF chromatin remodeling gene. To reveal its druggable vulnerabilities, we perform a compound screen and find that SCCOHT cells and tumors are sensitive to PARP inhibitors. Paradoxically, SCCOHT displays BRCA-deficient traits while retaining wild-type BRCA1 expression. This is caused by elevated R-loop accumulation in SCCOHT cells and tumors, which sequesters BRCA1 limiting its availability for DNA damage repair. Through proximity-dependent biotin identification approach using pathogenic SMARCA4 variants that retain protein expression, we uncover that SMARCA4 promotes RNA polymerase II (Pol II) elongation by mediating the assembly of the polymerase-associated factor 1 (PAF1) complex and its association with Pol II. Thus, SMARCA4 loss increases Pol II pausing, resulting in elevated R-loops and BRCA1 redistribution. This leads to the sensitivity of SCCOHT cells and tumors to PARP inhibitors, which is further enhanced by addition of a CDK9 inhibitor targeting Pol II elongation. Our findings reveal a link between SMARCA4 loss and perturbed Pol II elongation causing hampered BRCA1 repair, which can be exploited therapeutically to target SCCOHT. (These studies were supported by Canadian Institute of Health Research (CIHR) grants PJT-156233 and PJT-438303).

ORGANISM(S): Homo sapiens

PROVIDER: GSE275845 | GEO | 2025/04/24

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

SMARCA4-loss increases RNA Polymerase II pausing and elevates R-loops to inhibit BRCA1-mediated repair in ovarian cancer

Project description:Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare and aggressive cancer mainly affecting young women. It is driven by inactivating mutations in SMARCA4 (BRG1), a key SWI/SNF chromatin remodeling gene. To reveal its druggable vulnerabilities, we perform a compound screen and find that SCCOHT cells and tumors are sensitive to PARP inhibitors. Paradoxically, SCCOHT displays BRCA-deficient traits while retaining wild-type BRCA1 expression. This is caused by elevated R-loop accumulation in SCCOHT cells and tumors, which sequesters BRCA1 limiting its availability for DNA damage repair. Through proximity-dependent biotin identification approach using pathogenic SMARCA4 variants that retain protein expression, we uncover that SMARCA4 promotes RNA polymerase II (Pol II) elongation by mediating the assembly of the polymerase-associated factor 1 (PAF1) complex and its association with Pol II. Thus, SMARCA4 loss increases Pol II pausing, resulting in elevated R-loops and BRCA1 redistribution. This leads to the sensitivity of SCCOHT cells and tumors to PARP inhibitors, which is further enhanced by addition of a CDK9 inhibitor targeting Pol II elongation. Our findings reveal a link between SMARCA4 loss and perturbed Pol II elongation causing hampered BRCA1 repair, which can be exploited therapeutically to target SCCOHT. (These studies were supported by Canadian Institute of Health Research (CIHR) grants PJT-156233 and PJT-438303).

2025-04-24 | GSE275694 | GEO

SMARCA4-loss increases RNA Polymerase II pausing and elevates R-loops to inhibit BRCA1-mediated repair in ovarian cancer

2025-04-24 | GSE290811 | GEO

Gene expression in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) cell line COV434

2025-04-02 | GSE217699 | GEO

Re-expression of SMARCA4/BRG1 in Small Cell Carcinoma of Ovary, Hypercalcemic Type (SCCOHT) promotes an epithelial-like gene signature through an AP-1-dependent mechanism

Project description:Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare and aggressive form of ovarian cancer. SCCOHT tumors have inactivating mutations in SMARCA4 (BRG1), one of the two mutually exclusive ATPases of the SWI/SNF chromatin remodeling complex. To address the role that BRG1 loss plays in SCCOHT tumorigenesis, we performed integrative multi-omic analyses in SCCOHT cell lines +/- BRG1 re-expression. BRG1 re-expression induced a gene and protein signature similar to an epithelial cell and gained chromatin accessibility sites correlated with other epithelial originating TCGA tumors. Furthermore, AP-1 motifs were enriched at the promoters of highly upregulated epithelial genes. Using a dominant negative AP-1 cell line, we found that both AP-1 DNA binding activity and BRG1 re-expression are necessary for the gene and protein expression of epithelial genes. Our study demonstrates that BRG1 re-expression drives an epithelial-like gene and protein signature in SCCOHT cells that depends upon AP-1 activity.

2021-01-15 | PXD014134 | Pride

Gene Expression of Small Cell Carcinoma of the Ovary, hypercalcemic type.

Project description:Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT) is a rare and aggressive form of ovarian cancer afflicting young women at a median age of 24 years. SCCOHTs are characterized by loss of protein expression of SWI/SNF chromatin remodeling ATPases SMARCA4 and SMARCA2 through mutation and epigenetic silencing, respectively. This study aims to establish gene expression profiles of this cancer through RNA-Seq of four pathologically confirmed cases of SCCOHT tumors.

2018-02-20 | GSE109919 | GEO

CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary (II)

Project description:Inactivating mutations in SMARCA4 (BRG1), a key SWI/SNF chromatin remodelling gene, underlie small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). To reveal its druggable vulnerabilities, we perform kinase-focused RNAi screens and uncover that SMARCA4-deficient SCCOHT cells are highly sensitive to the inhibition of cyclin-dependent kinase 4/6 (CDK4/6). SMARCA4 loss causes profound downregulation of cyclin D1, which limits CDK4/6 kinase activity in SCCOHT cells and leads to in vitro and in vivo susceptibility to CDK4/6 inhibitors. SCCOHT patient tumors are deficient in cyclin D1 yet retain the retinoblastoma-proficient/p16INK4a-deficient profile associated with positive responses to CDK4/6 inhibitors. Thus, our findings indicate that CDK4/6 inhibitors, approved for a breast cancer subtype addicted to CDK4/6 activation, could be repurposed to treat SCCOHT. Moreover, our study suggests a novel paradigm whereby critically low oncogene levels, caused by loss of a driver tumor suppressor, may also be exploited therapeutically.

2019-02-04 | GSE120298 | GEO

CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary (I)

2019-02-04 | GSE120297 | GEO

Atypical teratoid/rhabdoid tumors (ATRTs) with SMARCA4 mutation are molecularly distinct from SMARCB1 deficient cases

Project description:Genome wide DNA methylation profiling of ATRTs and extracranial malignant rhabdoid tumors (eMRTs) samples harboring mutations in SMARCA4 and of small cell carcinoma of the ovary hypercalcemic type (SCCOHT) was performed . The Illumina Infinium HumanMethylation450 BeadChip and the Illumina Infinium MethylationEPIC arrays were used to obtain DNA methylation profiles across approximately 450,000 CpGs and 850,000 CpGs, respectively, in FFPE derived tumor samples. In total n=14 ATRT, n=6 eMRTs and n=28 SCCOHT samples were analyzed.

2020-12-18 | GSE161692 | GEO

ena-DATASET-BCCA-25-03-2014-21:27:54:915-539 - samples

Project description:Small cell carcinoma of the ovary of hypercalcemic type (SCCOHT) is an extremely rare, aggressive cancer affecting children and young women. We identified germline and somatic inactivating mutations in the SWI/SNF chromatin-remodeling gene SMARCA4 in 75% (9/12) of SCCOHT patients in addition to SMARCA4 protein loss in 82% (14/17) of SCCOHT tumors, but in only 0.4% (2/485) of other primary ovarian tumors. These data implicate SMARCA4 in SCCOHT oncogenesis.

| EGAD00001000794 | EGA

ena-DATASET-BCCA-16-05-2014-18:07:21:146-126 - samples

| EGAD00001000850 | EGA